Aardvark Therapeutics Faces Securities Class Action Over IPO Disclosures

The complaint alleges that Aardvark Therapeutics failed to disclose critical safety risks associated with its flagship development program. Plaintiffs claim that management overstated the clinical and commercial potential of ARD-101, leading to false and misleading public statements throughout the class period. These alleged omissions came to light on February 27, 2026, when the company announced a voluntary pause of its Phase 3 HERO clinical trial.

Aardvark cited reversible cardiac observations identified during routine safety monitoring in a healthy volunteer study as the catalyst for the suspension. The market reacted sharply to the disclosure, sending Aardvark shares plummeting by 56.2%, or $7.02 per share, to close at $5.47 on March 2, 2026. The law firm Wolf Haldenstein Adler Freeman & Herz LLP is now representing investors seeking to recover losses linked to these events, citing the firm's history in securities litigation as a resource for those affected by the company's disclosures.